Literature DB >> 24837506

IFN-γ, but not IL-17A, is required for survival during secondary pulmonary Francisella tularensis Live Vaccine Stain infection.

Lydia M Roberts1, John S Davies1, Gregory D Sempowski2, Jeffrey A Frelinger3.   

Abstract

IL-17 and IFN-γ production by Th17 and Th1 cells, respectively, is critical for survival during primary respiratory infection with the pathogenic bacterium, Francisella tularensis Live Vaccine Strain (LVS). The importance, however, of these T cell subsets and their soluble mediators is not well understood during a secondary or memory response. We measured the number of CD4(+) T cells producing IFN-γ or IL-17 in the spleen and lungs of vaccinated mice on day four of the secondary response using intracellular cytokine staining in order to identify protective T cell subsets participating in the memory response. Few bacteria were present in spleens of vaccinated mice on day four and a T cell response was not observed. In the lung, where more bacteria were present, there was a robust Th1 response in vaccinated mice but Th17 cells were not present at higher numbers in vaccinated mice compared to unvaccinated mice. These data show that the lung is the dominant site of the secondary immune response and suggest that Th17 cells are not required for survival during secondary challenge. To further investigate the importance of IFN-γ and IL-17 during the secondary response to F. tularensis, we neutralized either IFN-γ or IL-17 in vivo using monoclonal antibody treatment. Vaccinated mice treated with anti-IFN-γ lost more weight and had higher bacterial burdens compared to vaccinated mice treated with isotype control antibody. In contrast, treatment with anti-IL-17A antibody did not alter weight loss profiles or bacterial burdens compared to mice treated with isotype control antibody. Together, these results suggested that IFN-γ is required during both primary and secondary respiratory F. tularensis infection. IL-17, on the other hand, is only critical during the primary response to respiratory F. tularensis but dispensable during the secondary response.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Francisella tularensis; IL-17; Interferon-gamma; Intranasal; Secondary response; clpB

Mesh:

Substances:

Year:  2014        PMID: 24837506      PMCID: PMC4075325          DOI: 10.1016/j.vaccine.2014.05.013

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  29 in total

Review 1.  The Clp proteins: proteolysis regulators or molecular chaperones?

Authors:  C Squires; C L Squires
Journal:  J Bacteriol       Date:  1992-02       Impact factor: 3.490

2.  In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies.

Authors:  D A Leiby; A H Fortier; R M Crawford; R D Schreiber; C A Nacy
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

3.  Loss of either CD4+ or CD8+ T cells does not affect the magnitude of protective immunity to an intracellular pathogen, Francisella tularensis strain LVS.

Authors:  D Yee; T R Rhinehart-Jones; K L Elkins
Journal:  J Immunol       Date:  1996-12-01       Impact factor: 5.422

4.  Biological warfare. A historical perspective.

Authors:  G W Christopher; T J Cieslak; J A Pavlin; E M Eitzen
Journal:  JAMA       Date:  1997-08-06       Impact factor: 56.272

5.  Importance of B cells, but not specific antibodies, in primary and secondary protective immunity to the intracellular bacterium Francisella tularensis live vaccine strain.

Authors:  K L Elkins; C M Bosio; T R Rhinehart-Jones
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

6.  Increased susceptibility of IgA-deficient mice to pulmonary Francisella tularensis live vaccine strain infection.

Authors:  Yoichi Furuya; Girish S Kirimanjeswara; Sean Roberts; Dennis W Metzger
Journal:  Infect Immun       Date:  2013-07-08       Impact factor: 3.441

7.  Construction and characterization of a Helicobacter pylori clpB mutant and role of the gene in the stress response.

Authors:  E Allan; P Mullany; S Tabaqchali
Journal:  J Bacteriol       Date:  1998-01       Impact factor: 3.490

8.  The requirement for gamma interferon in resistance of mice to experimental tularemia.

Authors:  L S Anthony; E Ghadirian; F P Nestel; P A Kongshavn
Journal:  Microb Pathog       Date:  1989-12       Impact factor: 3.738

9.  Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies.

Authors:  J Wayne Conlan; Wangxue Chen; Hua Shen; Ann Webb; Rhonda KuoLee
Journal:  Microb Pathog       Date:  2003-05       Impact factor: 3.738

10.  Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background.

Authors:  Wangxue Chen; Hua Shen; Ann Webb; Rhonda KuoLee; J Wayne Conlan
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

View more
  15 in total

1.  Mouse Model of a Human STAT4 Point Mutation That Predisposes to Disseminated Coccidiomycosis.

Authors:  Daniel A Powell; Amy P Hsu; Lisa F Shubitz; Christine D Butkiewicz; Hilary Moale; Hien T Trinh; Thomas Doetschman; Teodora G Georgieva; Dakota M Reinartz; Justin E Wilson; Marc J Orbach; Steven M Holland; John N Galgiani; Jeffrey A Frelinger
Journal:  Immunohorizons       Date:  2022-02-11

2.  Mice Housed at Elevated Vivarium Temperatures Display Enhanced T-cell Response and Survival to Francisella tularensis.

Authors:  Robert L Rubin
Journal:  Comp Med       Date:  2017-12-01       Impact factor: 0.982

3.  Viable spores of Coccidioides posadasii Δcps1 are required for vaccination and provide long lasting immunity.

Authors:  Lisa F Shubitz; Daniel A Powell; Hien T Trinh; M Lourdes Lewis; Marc J Orbach; Jeffrey A Frelinger; John N Galgiani
Journal:  Vaccine       Date:  2018-04-30       Impact factor: 3.641

4.  Inclusion of Epitopes That Expand High-Avidity CD4+ T Cells Transforms Subprotective Vaccines to Efficacious Immunogens against Virulent Francisella tularensis.

Authors:  Lydia M Roberts; Deborah D Crane; Tara D Wehrly; Joshua R Fletcher; Bradley D Jones; Catharine M Bosio
Journal:  J Immunol       Date:  2016-08-19       Impact factor: 5.422

5.  Live Vaccination Generates Both Disease Tolerance and Host Resistance During Chronic Pulmonary Infection With Highly Virulent Francisella tularensis SchuS4.

Authors:  Alicia M Soucy; Gregory J Hurteau; Dennis W Metzger
Journal:  J Infect Dis       Date:  2018-10-20       Impact factor: 5.226

Review 6.  Differential Immune Response Following Intranasal and Intradermal Infection with Francisella tularensis: Implications for Vaccine Development.

Authors:  McKayla J Nicol; David R Williamson; David E Place; Girish S Kirimanjeswara
Journal:  Microorganisms       Date:  2021-04-30

7.  TLR2 Signaling is Required for the Innate, but Not Adaptive Response to LVS clpB.

Authors:  Lydia M Roberts; Hannah E Ledvina; Gregory D Sempowski; Jeffrey A Frelinger
Journal:  Front Immunol       Date:  2014-09-05       Impact factor: 7.561

8.  Vaccination with Klebsiella pneumoniae-derived extracellular vesicles protects against bacteria-induced lethality via both humoral and cellular immunity.

Authors:  Won-Hee Lee; Hyun-Il Choi; Sung-Wook Hong; Kwang-Sun Kim; Yong Song Gho; Seong Gyu Jeon
Journal:  Exp Mol Med       Date:  2015-09-11       Impact factor: 8.718

9.  Development of a novel Francisella tularensis Live Vaccine Strain expressing ovalbumin provides insight into antigen-specific CD8+ T cell responses.

Authors:  David E Place; David R Williamson; Yevgeniy Yuzefpolskiy; Bhuvana Katkere; Surojit Sarkar; Vandana Kalia; Girish S Kirimanjeswara
Journal:  PLoS One       Date:  2017-12-28       Impact factor: 3.240

10.  An Improved Tobacco Mosaic Virus (TMV)-Conjugated Multiantigen Subunit Vaccine Against Respiratory Tularemia.

Authors:  Ahd A Mansour; Sukalyani Banik; Ragavan V Suresh; Hardeep Kaur; Meenakshi Malik; Alison A McCormick; Chandra S Bakshi
Journal:  Front Microbiol       Date:  2018-06-05       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.